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Abstract
Background: Although combination antiretroviral therapy (cART) initiated in the acute phase of HIV-1 infection may prevent
expansion of the latent reservoir, its benefits remain controversial. In the current study, HIV-1 RNA transcription patterns in
peripheral blood mononuclear cells (PBMC) were monitored during acute cART to assess the effect of early treatment on
cellular viral reservoirs.
Methodology/Principal Findings: Acutely HIV-1 infected patients (n=24) were treated within 3–15 weeks after infection.
Patients elected to cease treatment after $1 year of therapy. HIV-1 DNA (vDNA), HIV-1 RNA species expressed both in
latently and productively infected cells, unspliced (UsRNA), multiply spliced (MsRNA-tatrev; MsRNA-nef), and PBMC-
associated extracellular virion RNA (vRex), expressed specifically by productively infected cells, were quantified in PBMC by
patient matched real-time PCR prior, during and post cART. In a matched control-group of patients on successful cART
started during chronic infection (n=15), UsRNA in PBMC and vDNA were measured cross-sectionally. In contrast to previous
reports, PBMC-associated HIV-1 RNAs declined to predominantly undetectable levels on cART. After cART cessation, UsRNA,
vRex, and MsRNA-tatrev rebounded to levels not significantly different to those at baseline (p.0.1). In contrast, MsRNA-nef
remained significantly lower as compared to pretreatment (p=0.015). UsRNA expressed at the highest levels of all viral
RNAs, was detectable on cART in 42% of patients with cART initiated during acute infection as opposed to 87% of patients
on cART initiated during chronic infection (Fisher’s exact test; p=0.008). Accordingly, UsRNA levels were 105–fold lower in
the acute as compared to the chronic group.
Conclusion: Early intervention resulted in profound depletion of PBMC expressing HIV-1 RNA. This is contrary to chronically
infected patients who predominantly showed continuous UsRNA expression on cART. Thus, antiretroviral treatment
initiated during the acute phase of infection prevented establishment or expansion of long-lived transcriptionally active
viral cellular reservoirs in peripheral blood.
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Introduction
Current combination antiretroviral therapy (cART), despite its
potency in suppressing active viral replication [1,2] and its power
in reducing mortality and morbidity of HIV-1 infection [3,4], has
not resulted in eradication or induction of treatment-free periods
of remission of HIV-1 replication [5,6,7]. A pool of HIV-1 infected
long-lived latently infected memory T-lymphocytes has been
reported to be the major reservoir that confers HIV-1 infection
resilient to eradication [8,9,10]. The frequency of latently infected
cells was reported to range from 1 to 20 cells per 10
6 resting CD4
+
T-cells [9]. However, as these assays rely on technically
demanding ex-vivo outgrowth assays, their results likely underes-
timate the size of the latent reservoir. Recent studies used PCR-
based methods, in which latency had been defined as active viral
transcription in the absence of viral progeny production. The
resulting estimates of the size of the peripheral blood latent
reservoir were at least 5–10 times higher in resting CD4
+ T-cells
[11] as well as in total PBMC [12] when compared to viral
outgrowth assays [9]. Apart from cells in peripheral blood, other
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[16,17,18,19], the brain [20], and the genital tract [21], have been
reported to contribute to latent viral sanctuaries.
Due to the low expression levels of viral RNA in latently
infected cells [12,14,22,23,24] and viral antigens, the latent viral
reservoir is greatly inaccessible for adaptive and innate immune
defenses. It has been proposed that local bursts of viral replication
are initiated by immune activation in response to specific antigens
[25,26,27] or due to random self-activation by the viral
transactivator Tat [28]. In the presence of potent cART, such
bursts will be dead-ended, because the viral particles produced
may not initiate new rounds of infection. Conversely, after
cessation of cART, this process will lead to rapid viral rebound
[29] initiated stochastically from single or oligoclonal archival
proviruses [30].
Nevertheless, the canon that HIV-1 replication, as measured by
levels of plasma viremia, will inevitably proceed in the absence of
cART [31,32] or recur soon after its cessation [29,33] has been
challenged by important exceptions. Due to strong and specific
immunological responses, so called elite-controllers contain viral
replication to levels below a clinically relevant threshold (,50
copies/ml) in the absence of cART (reviewed in [34]). Further-
more, in some instances treatment initiated during the acute or
early phases of HIV-1 infection had resulted in control of viremia
after treatment cessation [35,36,37,38]. These anecdotal cases
have been used as precedents supporting early treatment. In
addition, two rationales have been proposed to affirm possible
benefits of early treatment of HIV-1, despite considerable side
effects [39,40,41] as well as costs [42,43], which need to be
considered in relation to decades of expected treatment time.
Paul Ehrlich’s paradigm to ‘‘hit early and hard’’ in treatment of
infectious disease [44] to limit spread of an infectious pathogen
and to contain its population size, toxicity, and its potential to
escape immunological and chemotherapeutic/medical control
[45] is still valid and accepted. This concept was substantiated
for HIV-1 by Strain et al., who showed that the size of latent
reservoirs was smaller in patients with treatment initiation in the
acute phase than in those who initiated cART during chronic
infection [46]. In addition to that, the notion that acute HIV-1
infection is generally associated with oligoclonal viral quasispecies
of low phylogenetic diversity [47,48], led to the hypothesis that by
early treatment viral escape to specific HIV-1 antibody- and
cytotoxic T-cell responses may be avoided or deferred resulting in
clinical benefit and/or virological control of the virus. This
concept was corroborated by a study showing that transmission of
multiple quasispecies was associated with faster disease progression
than mono- or oligoclonal primary infection [49]. Low viral
diversity has also been shown to be associated with modest but
significant control of viremia in chronic infection [50]. Moreover,
superinfection can lead to the loss of control of viremia
[51,52,53,54,55,56].
To elucidate these issues in the current study, intra- and
extracellular viral dynamics were assessed before, during, and after
treatment of acute HIV-1 infection. For this purpose HIV-1 RNA
transcription patterns in PBMC and levels of plasma viremia were
monitored. Comparison with a group of patients, who had
initiated cART during chronic infection, was performed cross-
sectionally. Unexpectedly, cell-associated viral RNA burden in
PBMC became mostly undetectable in the acutely infected patient
group. The levels of UsRNA, the most abundant cellular HIV-1
RNA in vivo, were at least one order of magnitude lower during
cART initiated in acute than in chronic infection. These results
strongly indicate that patients initiating cART in the acute phase
of infection may attain a substantial virological benefit from early
intervention.
Results
Kinetics of viral RNA levels in response to treatment and
cessation of cART
Acutely HIV-1 infected patients (n=24) were treated with
cART within 3–15 weeks after infection. Plasma viremia was
monitored using standard diagnostic quantitative PCR-assays
(qPCR) and PBMC-associated HIV-1 nucleic acids (figure 1) were
quantified by patient matched qPCR [11,12,57,58]. HIV-1 DNA
(vDNA) was assessed as a measure of total infected cells,
comprising latently and productively infected cells as well as cells
harboring defective genomes.
Figure 1. Map of HIV-1 amplica for qPCR assays. Splice acceptors and donor sites are shown by red and blue vertical lines, respectively. Exons
are depicted in grey bars. Blue dotted lines show documented or predicted splice events. Sense primers used in qPCR assays are depicted by red
arrows antisense/cDNA primers by blue arrows. Fluorescent hydrolysis probes [58] (FH-probes/TaqManH-probes) are shown by green/pink bars.
Assays for MsRNAs share a common antisense/cDNA primer and in some instances, when a probe for MsRNA-tatrev was not available, a common FH-
probe 39 of the splice-acceptor of the 2
nd major intron. Note that this map does not show mRNAs encoding Env because these transcripts were not
assessed in the current study.
doi:10.1371/journal.pone.0013310.g001
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PBMC-associated viral RNA species (vRNAs) were quantified:
unspliced RNA (UsRNA) and 2 types of multiply spliced encoding
tat and rev (MsRNA-tatrev) or nef (MsRNA-nef). These RNAs
were found to be expressed both in latently [12,23,59] and
productively infected cells, however, at much higher levels in the
latter cell population. As a marker for productively infected cells,
PBMC-associated extracellular virion RNA (vRex) was measured
[11,12,14,22,57].
Initiation of cART resulted in a decay of viral RNA production
(figure 2A/B left panel). Whereas plasma viremia followed kinetics
which were consistent with a 2–3 phasic exponential decay, vRex
dropped to undetectable levels almost instantly after initiation of
cART. Decay of UsRNA and MsRNAs was intermediate between
that of plasma viremia and vRex (data not shown). Upon cessation
of cART, rebound of HIV-1 nucleic acids occurred quickly in
plasma (figure 2A, right panel), but was apparently delayed in
PBMC (figure 2B, right panel, figure 3B).
Time to event analysis of HIV-1 RNA detection during and
after cART
To corroborate these observations and to extend them to
UsRNA and MsRNAs, empirical distributions of the proportions
of patients with detectable viral RNAs after initiation of cART
were plotted (figure 3A). Similarly, distribution of the proportion
of patients experiencing viral rebound after therapy cessation was
addressed (figure 3B). Upon initiation of cART, disappearance of
vRex took a median time of 4.5 weeks (quartiles 4, 6 weeks).
Taking into account that the second sample following baseline in
the current study was obtained at a median time of 4.4 weeks
(quartiles 4, 5 weeks) depletion of vRex occurred instantaneously
after cART initiation. MsRNAs declined significantly later to
undetectable levels (Mann-Whitney, p=0.002), namely within a
median time of 8.4 weeks (quartiles 5, 13 weeks). The next
parameter to reach its detection limit with a significant delay
compared to MsRNA (Mann-Whitney, p=0.003) was UsRNA
with a median time to the first undetectable measurement of 13.5
weeks (quartiles 9, 47 weeks). Finally, plasma viremia dropped to
Figure 2. Longitudinal course of HIV-1 virion production. Levels
of plasma viremia (A) and of PBMC-associated virions, vRex (B)o f2 4
acutely infected patients, were plotted against time after initiation of
cART (0 weeks, left panels) or against time after cART cessation (defined
as 0 weeks in the right panels). Note that some data points are depicted
in the left panels are also shown in the right panels to facilitate
visualization of the effects of cART cessation. The amount of vRex
measurements is lower, because cell sampling was done less frequently
than plasma HIV-RNA was measured. Data within the grey horizontal
areas show PCR-negative samples below the detection limit of the
assays applied. The black line in panel A depicts the clinically used
threshold for plasma viremia of 50 RNA copies/ml.
doi:10.1371/journal.pone.0013310.g002
Figure 3. Empirical distribution of times to virological end-
points. Time to event analysis showing the percentage of patients
before reaching their first PCR-negative measurement after initiation of
cART (A) or reaching measurable viral RNA levels above a defined
threshold after cessation of cART (B). Thresholds are indicated in
parentheses in panel B and were defined as approximately 3-fold
elevation over mean on cART levels for cellular HIV-1 RNAs. Threshold of
plasma viremia was set at 50 copies/ml. On average vRex (red lines),
MsRNAs (magenta), UsRNA (blue) and plasma viremia (red broken lines)
dropped to undetectable levels 4.5, 8.4, 13.5, and 24.6 weeks after
initiation of cART, respectively (A) and rebounded within 17.9, 9.8, 8.0,
and 4.2 weeks after treatment cessation (B), (dotted lines). Note that for
analysis of plasma viremia only time-points were considered for which
also UsRNA and MsRNA measurements had been available.
doi:10.1371/journal.pone.0013310.g003
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12, 44 weeks), which was not significantly different to the decay of
UsRNA (Mann-Whitney, p=0.52). In general, after detection of
the first undetectable HIV RNA value, all RNA species measured
remained undetectable at almost all timepoints measured during
treatment.
After cessation of cART, plasma viremia reached levels above
the threshold of 50 copies/ml in a median time of 4.2 weeks
(quartiles 3, 10 weeks). Rebound of UsRNA and MsRNA
proceeded with some delay without reaching statistical difference
(Mann-Whitney, p=0.30 and p=0.07, respectively): Median time
to rebound was 8.0 weeks (quartiles 4, 12 weeks) and 9.8 weeks
(quartiles 4, 19 weeks) for UsRNA and MsRNA, respectively.
Lastly, within a median time of 17.9 weeks (quartiles 8, 56 weeks)
vRex rose to detectable levels. Its rebound was statistically
different from that of plasma viremia and of UsRNA (Mann-
Whitney, p=0.007 and 0.02, respectively) but not from MsRNA
(Mann-Whitney, p=0.06). It has to be noted that vRex was
measured less frequently than plasma or PBMC viremia.
Therefore the median time to rebound may have been
overestimated.
Magnitude of viral nucleic acid levels at baseline and
post-cessation
To investigate whether cART initiated in acute infection had an
impact beyond its cessation, the levels of HIV-1 nucleic acids at
baseline and after treatment cessation were compared. Maxima
were used to represent post-cessation HIV-1 nucleic acid levels, to
account for the variability among the different parameters
regarding the time to reach stable set-points.
Plasma viremia (figure 4A) was significantly reduced after
treatment cessation as compared to baseline (Wilcoxon signed
rank test, p=0.002). This reduction can be attributed in part to
the early treatment effect of cART (Gianella, von Wyl et al.,
unpublished data), but also to a naturally occurring ‘‘first peak’’ of
viremia observed in acute HIV-1 infection [60]. We observed a
less pronounced impact of early cART on cellular viral nucleic
acid levels after treatment cessation. Only MsRNA-nef showed
persistent significant reduction after cART (Wilcoxon signed rank
test, p=0.02), whereas the remaining parameters, vDNA, vRex,
UsRNA, and MsRNA-tatrev (figure 4B–E) tended to be lower
after treatment stop compared to baseline but without reaching
statistical significance (Wilcoxon signed rank test, p.0.10).
Figure 4. Virological parameters before, during, and after cART. Viral nucleic acid levels at baseline (diamonds), and average values during
the time windows defined as on cART (circles, vRex $2 weeks, plasma viremia, PBMC-associated UsRNA and MsRNAs $24 weeks) and post-cessation
maximal values (triangles). Data-points within the grey horizontal areas show PCR-negative samples below the detection limit of the assays applied.
P-values within panels show significance levels (Wilcoxon signed rank test) between baseline and post-cessation. Bars show medians and quartiles.
The dotted line in panel A depicts the clinically used threshold for plasma viremia of 50 RNA copies/ml.
doi:10.1371/journal.pone.0013310.g004
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As opposed to baseline and post-cessation viral nucleic acid
levels, which were represented by single measurements, on-cART
levels were estimated by calculating means. Taking into account
the rapid decay of vRex, the mean of samples at time-points $2
weeks after initiation of treatment was used. For all other
parameters measurements taken at time points $24 weeks were
used for calculation of mean values. The rationale for choosing this
time-window was that the parameter with the slowest decay
kinetics, plasma viremia, reached undetectable levels within a
median time of around 24 weeks as shown in figure 3A.
Accordingly, the resulting mean values for plasma viremia on
cART were well below the clinically used threshold of 50 copies/ml
(figure 4A), except for one patient (#133; 59 copies/ml).
HIV-1 DNA persisted at a level of 8236253 copies/10
6 PBMC
(mean6sem) during cART initiated in acute infection. However,
proviruses in these infected cells were transcriptionally almost
completely silent. Expression of MsRNAs and vRex was mostly
undetectable and attenuated to mean levels ,1 copy/10
6 PBMC
(MsRNA-tatrev: 0.3460.24, MsRNA-nef: 0.6560.30, vRex:
0.2960.19; mean6sem). Only expression of UsRNA was
occasionally detected at a mean level of 2.661.2 copies/10
6
PBMC. The absence of vRex during cART observed in the
current study was similar to findings of previous studies
[11,12,14,22] indicating a fast and complete loss of productively
infected cells as a consequence of cART. However, the almost
complete depletion of MsRNA and the profound reduction of
UsRNA were highly unexpected, as we and others have shown
their presence at measurable levels in latently infected cells of
HIV-1 infected patients on cART [11,12,59].
Comparison of the effects of cART initiated in primary
versus chronic infection
To investigate whether the observed depletion of viral
transcription could be attributed to the early initiation of cART,
PBMC obtained from patients, who had initiated antiretroviral
therapy in the chronic phase of HIV-1 infection, were assessed for
the presence of viral RNA in PBMC. Latently infected cells
expressing solely UsRNA had been shown to persist during cART
at the highest frequency among all cell classes expressing viral
RNA and UsRNA had been consistently detected at the highest
levels during cART in previous studies [11,12,57,61]. Therefore,
UsRNA and vDNA were quantified in patients in whom cART
had been initiated during chronic infection (n=15, for patient
characteristics see Table S1) using identical conditions as for the
acute patient group, including RNA extraction, use of patient
matched primers, and PCR input volumes. Levels of plasma
viremia in the chronic control group were ,50 copies/ml (mean:
10 copies/ml, range 0–28) and treatment had lasted for a median
time of 50 weeks (36–183 weeks). In this group of patients, 86% of
specimens were positive for UsRNA, which is significantly higher
than the percentage of patients in the acute group showing any
UsRNA positive PCR on cART (42%, Fisher’s exact test,
p=0.008). Furthermore, the average level of UsRNA in the
chronic control group (mean=272 copies/10
6 cells, range 0–
1486) was 105-fold higher than in the acute group (Mann-
Whitney, p,0.0001, figure 5A).
Levels of vDNA were significantly elevated (Mann-Whitney,
p=0.04) in the chronic group as compared to the patients treated
during acute infection. To adjust for this difference in the total
number of infected cells, the average viral transcriptional rate i.e.,
the ratio of viral RNA to vDNA, was calculated [11]. Similarly as
the absolute levels of UsRNA, viral transcriptional rates were
elevated with high statistical significance (12-fold, Mann-Whitney,
p=0.0002) in the chronic group as compared to patients in the
acute group (figure 5B).
Discussion
The main aims and rationales for antiretroviral therapy in acute
HIV-1 infection are confinement of genetic diversity of viral
quasispecies to prevent escape from adaptive immunity, restriction
of CD4
+ T-cell loss, preservation of immune functions, and
inhibition of initial viral spread throughout the possible sites of
replication. Despite considerable efforts from various research
Figure 5. Viral nucleic acid expression in acute and chronic patients during cART. Mean levels of vDNA (grey symbols) and UsRNA (blue
symbols) (A) or viral transcription rates (B) of patients that had initiated cART during acute infection (acute, n=24, circles) were assessed during the
on-cART time window ($24 weeks) and compared to single measurements in patients that had initiated cART during chronic infection (chronic,
n=15, triangles, median treatment time 50 weeks, range 36–183, see Table S1 for details). Data-points within the grey horizontal areas show PCR-
negative samples below the detection limit of the assays applied. P-values within panels show significance levels (Mann-Whitney test) between the
acute and the chronic group. Bars show medians and quartiles.
doi:10.1371/journal.pone.0013310.g005
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empirically substantiate these concepts remains limited. Here we
performed a longitudinal in-depth analysis using patient matched
highly sensitive qPCR assays to detect different HIV-1 gene
trancripts to assess effects of early treatment on cellular reservoirs
of HIV-1 in peripheral blood.
HIV-1 transcription was monitored longitudinally before,
during, and after cessation of treatment of acute HIV-1 infection
in well characterized patients [60,62]. This analytical approach
was applied because numerous studies revealed persistence of
cellular HIV-1 RNA for years in patients on cART despite
suppression of plasma viremia [14,15,17,57,61,63,64,65]. By
choosing a patient matched approach for qPCR with single copy
sensitivity, it was anticipated that not only levels of UsRNA, but
also the less abundant multiply spliced RNAs could be quantified
and used to assess the viral transcription pattern of the PBMC
reservoir of HIV-1 during cART [11,12,57].
The major finding of this study was that early cART initiated
during acute HIV-1 infection significantly depleted the number of
transciptionally active proviruses by an order of magnitude when
compared to levels detected in patients treated during chronic
infection.
Specifically, productively infected PBMC, hallmarked by
expression of cell attached virions (vRex) were depleted within a
median time of 4.5 weeks after cART initiation. The remaining
HIV-1
+ PBMC, expressing solely intracellular viral RNA, can
therefore be viewed as latently infected [11,12,14]. These cells
faced depletion within a median time of 24 weeks. This resulted in
.100-fold reduction of viral transcription levels and at least 10-
fold lower average viral transcriptional rates as compared to
patients who had started cART during chronic infection. It is
unlikely that the strong reduction of viral transcription in PBMC
in primary HIV infected patients was due to the potency of
treatment rather than to timing of antiretroviral therapy because
the control group of chronically infected patients received similar
treatment.
Decay of HIV-1
+ cells in response to treatment occurred in a
significantly staggered mode according to their pattern of viral
RNA expression and life-span as previously described [12].
Productively infected cells expressing vRex vanished almost
instantly after initiation of treatment, then cells expressing
MsRNA followed with a delay of about 4 weeks, ultimately a
further 5 weeks later, cells expressing solely UsRNA pursued.
Thus, even HIV-1 RNA expressing cells with the longest life spans
[12] approached depletion.
These findings imply that early cART led to the clearance of
long-lived cells harboring transcriptionally active latent proviruses.
In an early study, Markowitz and colleagues showed persistence of
viral transcription in PBMC when antiretroviral therapy was
initiated within 90 days after onset of primary symptoms [17]. This
discrepancy can most likely be explained by a 5–6 week earlier
initiation of therapy in the present study. Of note, our findings are
in agreement with the observations of Strain and colleagues [46].
In their study, using viral outgrowth assays of resting CD4
+ T-
lymphocytes, a cohort of patients on early cART showed lower
levels of latently infected cells than a control group with deferred
cART initiation. In addition, two small studies in humans and in
the SIV model also suggest that HIV-1 suppression as measured
by unspliced HIV-1, respectively SIV RNA can be reduced by
treatment during primary HIV infection in the gut associated
lymphoid tissue [66,67].
After cessation of cART, virological parameters reappeared
inverted to their decay. UsRNA rose to significant levels after 8
weeks, followed two weeks later by MsRNA and finally vRex
reappeared with a significant delay. The observations that viral
rebound in plasma preceded that of cellular viral RNAs and
plasma viremia was the last parameter to decay during cART,
implies that PBMC can be viewed as independent compartment to
some degree separate from the source of virus appearing in
plasma. These dynamics potentially suggest that repopulation of
the PBMC compartment of rebounding transcriptionally active
PBMC was most likely due to ‘‘de novo’’ infection of PBMC by
plasma virions rather than by reactivation of latently infected
PBMC. The rebounding virus most likely originates from distinct
compartments such as the secondary lymphoid organs (e.g., gut
associated lymphoid tissue (GALT), lymph nodes, spleen), the
cerebral nervous system, the kidneys, or the genital tract. Very
recent data by Yukl et al. [19] suggests that most likely more than
83% of all HIV-1 infected cells under therapy are to be found in
the GALT and that the RNA/DNA ratio on treatment tends to be
higher in this compartment than in the peripheral blood.
Furthermore, GALT is continuously exposed to bacterial antigenic
stimuli from gut commensals. In aggregate, the high HIV burden
together with continuous antigenic stimulation makes this large
reservoir a prominent candidate as a source for the rebounding
virus. Of note, the RNA/DNA ratios of GALT and PBMC in the
study by Yukl was measured with exactly the same methods as in
our study.
The fact that post-cessation control of viral RNA expression was
achieved in several patients during the post treatment observation
period supports this hypothesis: Plasma viremia was undetectable
in patient #72, control of UsRNA expression was experienced in
patient #25, control of MsRNA expression was achieved by
patients #25, #56, and #92, and control of vRex was
experienced by patients #72 and #99.
The observation that MsRNA-nef levels, a parameter reported
to be associated with viral latency [57,68] were significantly
reduced as compared to baseline further indicates that the latent
reservoir was reduced by initiation of cART during acute
infection. Conversely, it cannot be fully excluded that the
decreased levels of MsRNA-nef after therapy cessation may be
explained by the ‘‘first peak’’ of viral replication in acute HIV-1
infection and its subsequent spontaneous decay independent of
cART [69].
Taken together, our data demonstrate a profound virologic
effect of treatment initiation during acute HIV-1 infection. The
unprecedented finding that residual viral transcription was almost
completely depleted, suggests that the latent reservoir of HIV-1
during cART can be reduced by early intervention and that proof
of concept studies aiming at HIV-1 eradication or remission of
HIV-1 replication should be initiated in patients during acute
infection.
Materials and Methods
Ethics Statement
In accordance with the guidelines of the Ethics Committee of
the University Hospital of Zurich, written informed consent was
obtained from all participants of the studies analyzed: the Zurich
Primary HIV Study (ZPHI), the Swiss Spanish Intermittent
Therapy Trial (SSITT), and the Zurich HIV-1 Transcription
Study.
Patients and specimens
Patients with treatment initiated in the acute phase of
HIV-1 infection (acute group). Patients (n=24; Table S1)
included in our study were enrolled in the Zurich Primary HIV
Study (ZPHI, http://clinicaltrials.gov, NCT00537966) [62] a
HIV RNA in Primary Infection
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13310substudy of the Swiss HIV Cohort Study (SHCS). All 24 subjects
had a documented acute or recent primary HIV-1 infection at
presentation. Estimation of time after infection was as described by
Rieder et al [60]. Patients were included in the analysis only if
sequences were available to match primers in pol, tat, and env.
Blood samples were collected at the day of the very first cART
application (=baseline sample), longitudinally during treatment,
and after treatment cessation. EDTA-blood samples were collected
and separated into cells and plasma according to standard
procedures [22]. Cellular material was split into aliquots, each
comprising 2 million cells, and finally stored at 280uC as dry cell
pellets. Sampling of specimens for analysis of plasma viremia and
cellular nucleic acids was performed as described in Methods S1.
All patients were extensively tested for genotypic drug resistance:
Only one patient showed the D67N mutation at baseline in the
routine genotyping test and in addition, one patient showed 0.02%
K103N and one 2.4% M184V harboring minority species [62].
Patients with treatment initiated in the chronic phase of
HIV-1 infection (chronic group). PBMC samples for a cross-
sectional control group of 15 patients treated in the chronic phase
after seroconversion were obtained from the Swiss Spanish
Intermittent Therapy Trial (SSITT) [33] at the last time-point
before treatment cessation. In addition, specimens collected for
The Zurich HIV-1 Transcription Study (INFZ VTA 02.00 [12])
were analyzed (n=9). As in the acute group, patients in the
chronic group participated also in the Swiss HIV Cohort Study
(SHCS) and HIV-1 pol-sequences were available from the SHCS
genotypic drug resistance database [70]. Patient characteristics of
the chronic group are listed in Table S1.
Nucleic acid extraction/preparation
Total PBMC RNA was extracted with the RNeasy extraction
kit on the ‘QIAcube’ extraction device (Qiagen Hombrechtikon,
Switzerland) using an initial volume of 0.35 ml for cell lysis,
DNAse I digestion on the extraction column and a final elution
volume of 0.1 ml.
Selective isolation of PBMC-associated extracellular, virion-
encapsidated genomic HIV-RNA, vRex, free of intracellular
nucleic acid, was performed as described [14,22,71] using an
elution volume of 0.1 ml. Preparation of protease digested total
cell-lysates for DNA quantification was performed according to
Christopherson et al. [72] with minor modifications [11].
Design of HIV-1 patient matched qPCR
To ensure accurate quantification a patient matched approach
reaching single copy sensitivity was used for qPCR measurements
of RNA and vDNA [11,12,57,58] using specifically designed
fluorescent hydrolysis probes [58]. The location of qPCR primers
and probes is shown in figure 1; sequences are outlined in detail in
Table S2 and Methods S1. Individual sequence information to
adjust qPCR assays for UsRNA, vRex, and vDNA, was obtained
from the SHCS genotypic drug resistance database (HIV-1 pol-
sequences) [70].
To obtain sequence information to match qPCR primers and
probes for MsRNAs of predominant quasispecies, two regions
were amplified from each patients total DNA by a nested PCR
scanning approach as described [11] (positions 5833-6152 and
7992-8567 in the HXB2 genome, GenBank accession number
K03455).
As previously described [11,12,57] two different assays for
MsRNA were performed: MsRNA-total and MsRNA-tatrev from
which the MsRNA-nef was calculated using the difference in copy
numbers between the two measurements. To avoid redundancy,
MsRNA-total was not reported. Thus, only MsRNA-tatrev and
MsRNA-nef are shown in the current data-set and used for
statistical calculations. In 11% of measurements, it occurred that
copy numbers of MsRNA-total were nominally lower or equal to
MsRNA-tatrev. Calculation of MsRNA-nef was considered as not
applicable in these cases.
Quantitative real-time PCR measurements
Assays for RT-qPCR were performed as described [57,73] using
an ABI 7500 real-time thermocycler (Applied Biosystems,
Rotkreuz, Switzerland) with 0.005 mM ROX as passive reference,
0.2 mM fluorescent probe and 5 ml RNA as template in a final
volume of 35 ml aqueous phase plus 15 ml paraffin. Quantification
of vDNA was performed as described by Althaus et al. [58] in an
IQ5 real-time thermocycler (Biorad, Basel, Switzerland) in a
volume of 60 ml with 10 ml DNA template using HotStarTaq
master mix (QIAGEN, Hilden, Germany) supplemented with
PCR primers (1 mM each), probe (0.3 mM), and additional MgCl2
(1.5 mM) by incubation for 15 min at 95uC and 60 cycles of 10 s at
95uC, 5 s at 55uC and 40 s at 60uC.
Calculation of HIV-1 nucleic acid copy numbers from
qPCR data
Patient-nucleic acids were directly used to generate HIV-1
standard-curves. To obtain standard curves with maximal
dynamic range, baseline specimens were used as standards for
vDNA-measurements. Post-cessation time points with high plasma
viremia and high vDNA were chosen. Standards were prepared as
serial 3-fold dilutions in quadruplicates. Specimens other than the
ones chosen as standards were measured in duplicate.
Linear regression used in standard real-time PCR analysis was
applied for calculation of HIV-1 copy numbers:
Ct~IzS|log10 copy numbers ðÞ , ð1Þ
where I is the Y-axis intercept of the regression line, depicting the
point where Ct equals one copy (=10
0) and S is its slope. I and S
were determined as described in Methods S1. In cases where only
one duplicate HIV-1 PCR was positive and/or calculation resulted
in less than 1 nominal copy number per reaction, HIV-1 nucleic
acid copy numbers were censored to 1 copy per PCR [11,12].
Normalization to cellular input
To control for input and/or differences in qPCR efficiencies in
RNA PCR the expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) against a standard dilution series of in
vitro transcribed GAPDH RNA was measured in duplicates as
described previously [73] and in Methods S1. Linear regression, as
applied by the ABI7500 software, was used to evaluate GAPDH
measurements. Mean GAPDH-RNA copies per 10
6 cell equiva-
lents were empirically determined in PBMC specimens with
known cell numbers (2610
6 cells sample, n=310) resulting in a
conversion factor of 2.85610
7 copies GAPDH-RNA/10
6 PBMC.
Cellular input for DNA was quantified by beta-actin PCR using
primers and probe described in Methods S1. As quantification
standard for cellular input, 15 million PBMC were lysed in 1 ml
cell lysis buffer, serial two-fold dilutions were measured and
cellular input per PCR was calculated by linear regression using
the software provided with the IQ5-system. Both for vDNA and
viral RNA, the mean of duplicate PCR measurements was
normalized to cellular input and finally expressed as HIV-1 nucleic
acid copies per 10
6 PBMC.
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GraphPad Prism 5.0 software (GraphPad Software, San Diego,
CA) was used for statistical analyses. P,0.05 was considered as the
level of significance. Mann-Whitney testing was applied unless
otherwise indicated for group comparisons. Fisher’s exact test was
used in analysis of contingency tables. No adjustment for multiple
testing was applied.
Supporting Information
Table S1 Characteristics of patients.
Found at: doi:10.1371/journal.pone.0013310.s001 (0.01 MB
PDF)
Table S2 Oligoucleotides used for patient-specific qPCR.
Found at: doi:10.1371/journal.pone.0013310.s002 (0.10 MB
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Methods S1 Supplementary methods.
Found at: doi:10.1371/journal.pone.0013310.s003 (0.05 MB
PDF)
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